0 CHECKOUT

PRODUCT FILTERS

REGION

31
27
23
23
19

COUNTRY

10
8
7
4
3

PRICE

28
40
87
140

PUBLISHED

3
5
12
140

PRODUCT TYPE

134
2
1
1
1
1

Generics

The global generics market is fast growing, driven by demand for cost-effective medicines and new availability of high value products. By now there are 17 generic companies with revenues in excess of US$1 billion, while there were only 12 in 2008/09.

The reports, books, and subscriptions listed under Research and Markets’ Generics category cover every aspect of this industry, such as market trends, forecasts, drivers and restraints, etc. They will allow you to identify business opportunities and assess the strategies of the major players. You can also investigate the latest international and national patent opportunities across a vast number of INNs (international non-proprietary names), taking into account key concerns such as expiry dates, national regulations, etc.

Key players featured in our publications includes Teva Pharmaceutical, Mylan, Sandoz, Watson Pharmaceuticals, Greenstone, Par Pharma, Hospira, Apotex, Mallinckrodt, Dr. Reddy's, and more. Show Less
Read more

Active Pharmaceutical Ingredient Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, Nephrology, Ophthalmology) - Global Forecast to 2020

Factors such as the increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets...

Published:  October 2015
Price:  From

India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics

Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market’s reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the...

Published:  February 2015
Price:  From

Generic Drugs Market in Japan 2015-2019

About Generic Drugs A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded...

Published:  February 2015
Price:  From

Generic Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue

A generic drug is a pharmaceutical product that can be interchanged with the innovator product and is comparable with it in terms of dosage, intended use and efficacy. Generic drugs are manufactured...

Published:  November 2015
Price:  From

Generic Oncology Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue

Driven by rising cancer incidences, patent expiry of a number of blockbuster oncology drugs and the high cost of cancer treatment, the market for generic oncology drugs has been witnessing robust growth....

Published:  December 2015
Price:  From

Innovative Drug Delivery Systems Opportunities for Generic & Specialty Pharmaceutical Companies

There are more than 1400 sustained or controlled release drugs have been approved all over the world Revenues within the global generics market reached an estimated value of $265 b in 2012, showing...

Published:  February 2014
Price:  From

Global Generic Drugs Market 2014-2018

The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11 02 percent over the period 2013-2018 The patent expiry of top-selling drugs is one of the major drivers contributing to...

Published:  March 2014
Price:  From

Generic Drug Opportunity Assessment - Dronedarone (Multaq)

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Multaq...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Ambrisanten (Letairis)

The branded drug Ambrisentan (brand name Letairis) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Apixaban (Eliquis)

The branded drug Eliquis (apixaban) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Asenapine (Saphris)

The branded drug Asenapine (Saphris) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Avanafil (Stendra)

Stendra is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) Stendra received FDA NDA approval in April 2012 In June 2013, the drug, which will be marketed...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Boceprevir (Victrelis)

Boceprevir is a direct acting antiviral drug against the hepatitis C (HCV) virus It is an inhibitor (protease inhibitor) of the HCV non-structural protein 3 (NS3) serine protease Protease inhibitors...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Dabigatran (Pradaxa)

Pradaxa (dabigatran etexilate) is a novel reversible oral direct thrombin inhibitor that blocks the activity of thrombin, the central enzyme in clot formation It is approved for the primary prevention...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Eltrombopag (Promacta)

This branded that represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Promacta...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Fesoterodine (Toviaz)

This branded drug represents an attractive opportunity for generic drug companies Fesoterodine is an anticholinergic and competitive muscarinic receptor antagonist After oral administration, fesoterodine...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Fingolimod (Gilenya)

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Gilenya...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Granisetron Sancuso

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Sancuso...

Published:  January 2014
Price:  From

Generic Drug Opportunity Assessment - Etravirine (Intelence)

This branded drug represents an attractive opportunity for generic drug companies The Brand Intelence (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency...

Published:  January 2014
Price:  From

Innovative Drug Delivery Systems: Novel Products and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

There are more than 1400 sustained or controlled release drugs have been approved all over the world Revenues within the global generics market reached an estimated value of $265 b in 2012, showing...

Published:  June 2013
Price:  From
Loading Indicator

Our Clients